Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment

Official Title

Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment

Brief Summary

Chloroquine or hydroxychloroquine in COVID-19 treatment

Detailed Description

Clinical Study Evaluating the Efficacy of Chloroquine or hydroxychloroquine in COVID-19
treatment

Status

Completed

Conditions

COVID-19

Coronavirus Infection

Interventions

Drug: Chloroquine or Hydroxychloroquine

Chloroquine or Hydroxychloroquine
Other Name: alexoquine, chloroquine, Hydroquine

Eligibility Criteria

Inclusion Criteria:

- Covid 19 patients

Exclusion Criteria:

- Allergy or contraindication to the drug

- Pregnant or lactating

- Patients with cardiac problems

Eligibility Gender

All

Eligibility Age

Minimum: N/A ~ Maximum: N/A

Countries

Egypt

Locations

Tanta University, Assiut University
Tanta, Egypt

Investigators

sherief Abd-Elsalam, Ass. Prof., Principal Investigator
Tanta University - Faculty of Medicine

NCT Number

NCT04353336

MeSH Terms

COVID-19

Coronavirus Infections

Hydroxychloroquine

Chloroquine

Chloroquine diphosphate

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Tanta University

Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA